{{medical}}
{{Drugbox
| IUPAC_name        = (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate
| imagename         = 阿齐沙坦酯
| image             = Azilsartan medoxomil.svg
| IUPHAR_ligand = 6901
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 147403-03-0
| ATC_prefix = C09
| ATC_suffix = CA09
| ATC_supplemental =
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68850
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 57242
| PubChem = 9825285
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F9NUX55P23
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8001032
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08864
| synonyms = TAK-536
| C=30 | H=24 | N=4 | O=8 
| molecular_weight  = 568.5
| smiles            = Cc2oc(=O)oc2COC(=O)c4c1c(ccc4)nc(OCC)n1Cc(cc6)ccc6-c3ccccc3-c5nc(=O)on5
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}
'''阿齐沙坦'''（又稱'''阿齐沙坦酯'''，{{lang-en|Azilsartan|}}）（[[国际非专利药品名称|INN]]） 是一款正处于研发中的治疗[[高血压|高血压]]症的[[血管紧张素II受体拮抗剂|血管紧张素II受体拮抗剂]]药物，多用于治疗[[高血压|高血压]]症，也是目前唯一处于末期临床的血管紧张素II受体拮抗剂（沙坦类）药物。

==前體藥物==
作为[[前体药物|前体药物]]的'''阿齐沙坦酯''' （azilsartan medoxomil、INN、代码 TAK-491），2010年4月28日，日本[[武田制药|武田制药]]公司（Takeda）所研发的该药物完成了[[临床试验|三期临床试验]]，正在[[美国食品药品监督管理局|美国食品药品监督管理局]]审批中，预计2012年可拿到上市批文，<ref>{{cite web |url=http://www.clinicaltrials.gov/ct2/results?term=Azilsartan |title=Complete list of clinical trials for azilsartan (ClinicalTrials.gov) |format= |work= |accessdate=2008-06-20 |archive-date=2019-07-02 |archive-url=https://web.archive.org/web/20190702154015/https://clinicaltrials.gov/ct2/results?term=Azilsartan |dead-url=no }}</ref><ref>{{cite news |url=http://www.medscape.com/viewarticle/726187 |author=Collins TR |title=New ARB shows good results in blacks |publisher={{link-en|Medscape|Medscape}} |date=2010-08-02 |accessdate=2010-08-02 |archive-date=2012-01-14 |archive-url=https://web.archive.org/web/20120114003218/http://www.medscape.com/viewarticle/726187 |dead-url=no }}</ref>该药物為一種[[血管紧张素II受体拮抗剂|血管紧张素II受体拮抗剂]]，可單獨使用或與其它降血壓藥物一起使用<ref>{{cite web|url=http://www.severehypertension.net/hbp/more/takeda-submits-new-drug-application/|title=Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S.|author=Larkin, K. T., Taylor, B. K., Hernandez, D. H., Goodie, J. L., Doyle, A., O'Quinn, S. R.|publisher=severehypertension.net|date=2010-04-28|language=en|access-date=2011-02-07|archive-date=2018-01-20|archive-url=https://web.archive.org/web/20180120065617/http://www.severehypertension.net/hbp/more/takeda-submits-new-drug-application/|dead-url=no}}</ref>
，被视作[[坎地沙坦|坎地沙坦酯]]的下一代产品。

湯森路透社（Thomson Reuters）預測若該藥順利通過認證，在2014年時應可達到年銷售七億三百三十萬美元<ref name="reuters">{{cite web|url=http://www.reuters.com/article/2010/05/03/hypertension-takeda-idUSN0220734220100503|title=Takeda blood pressure drug tops rivals in studies|author=Bill Berkrot|publisher=reuters|date=2010-05-03|language=en|access-date=2011-02-07|archive-date=2013-10-31|archive-url=https://web.archive.org/web/20131031081834/http://www.reuters.com/article/2010/05/03/hypertension-takeda-idUSN0220734220100503|dead-url=yes}}</ref>。

==臨床實驗==
阿齐沙坦酯對於降低[[血壓|血壓]]有着较为顯著的疗效，一項1291位病人參與、長達六星期的實驗比較40[[毫克|毫克]]、80毫克的阿齐沙坦酯和40毫克的[[奥美沙坦|奥美沙坦酯]]（Benicar®、由第一制藥三共株式會社研發）或320毫克的[[纈沙坦|纈沙坦]]的效果，結果40毫克的阿齐沙坦酯可降低13.4mmHg的血壓、80毫克的阿齐沙坦酯則是14.5[[托|mmHg]]、40毫克的Benicar是12mmHg、320公克的纈沙坦則是10.2mmHg。<ref name="reuters"></ref>

另有一項为期六周的實驗，将20毫克、40毫克、80毫克的阿齐沙坦酯和40毫克的奥美沙坦酯进行了比较，共有1272位病人參與。結果显示，20毫克的阿齐沙坦酯能降血壓10.8mmHg、40毫克的阿齐沙坦酯則是12.1mmHg、80毫克的阿齐沙坦酯是13.2mmHg、40毫克的奥美沙坦酯則为11.2mmHg。<ref name="reuters"></ref>

==参考资料==
{{Reflist}}

==延伸閱讀==
{{refbegin}}
*{{cite web|url=http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Focus-on-Azilsartan-A-next-generation-angiotensin-/ArticleStandard/Article/detail/700419?contextCategoryId=44233|title=Focus on Azilsartan: A next-generation angiotensin II receptor blocker for the treatment of hypertension|date=2010-12-01|author=Jessica C. Song, MA, PharmD, Pritha Singh, Wilson Fung Fung|publisher=Formulary|language=en}}{{Dead link|date=2018年7月 |bot=InternetArchiveBot |fix-attempted=yes }}
*{{cite web|url=http://www.takeda.com/press/article_38490.html|title=Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension|author=Takeda Pharmaceutical Company Limited|date=2010-10-20|language=en|access-date=2011-02-07|archive-date=2012-05-10|archive-url=https://web.archive.org/web/20120510153625/http://www.takeda.com/press/article_38490.html|dead-url=no}}<small>此為[[武田製藥|武田製藥]]公司（Takeda）對產品的說明</small>
{{refend}}

{{基于肾素-血管紧张素系统的抗高血压药}}
{{Peptidergics}}

[[Category:武田药品工业|Category:武田药品工业]]
[[Category:血管紧张素II受体拮抗剂|A阿]]
[[Category:苯并咪唑类药物|A阿]]
[[Category:恶二唑|A阿]]
[[Category:氨基甲酸酯|A阿]]
[[Category:醚|A阿]]
[[Category:抗高血压药物|A阿]]
[[Category:缺少物质图片的化学品条目|Category:缺少物质图片的化学品条目]]